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PROBLEM
Melanoma is one of the most aggressive form of skin
cancer leads to 80% of skin cancer related deaths. The
current standard of care includes combination of
BRAF/MEK inhibitors which improves the prognosis for
melanoma patients, but most patients do not show
lasting response to this treatment.

BACKGROUND
Melanoma is the deadliest form of skin cancer. In the
initial stages, it can be treated successfully with surgery
and survival rates are higher, but after metastasis
survival rates drops significantly. Advanced/metastatic
melanoma is an aggressive cancer with a low survival
rate. The current standard of care - combination of
BRAF/MEK inhibitors improve the prognosis of
melanoma patients but most patients do not show
lasting response to this treatment [1-6]. The MAPK
pathway is constantly active in melanoma and
identifying other markers which can inhibit this pathway
and reduce resistance to therapy is important. Most
melanoma cells over express MGMT and over
expression leads to resistance to chemotherapeutic
agents [7] and inhibition of MGMT not only will reduce
the resistance but also enhance chemotherapeutic drug
effects more efficiently. Therefore, we combined MGMT
inhibitor (disulfiram-cu) along with BRAF/MEK inhibitors
which can inactivate the MAPK pathway more efficiently
and enhance malignant melanoma and metastatic cell
killing more effectively.

OBJECTIVE
O6 methylguanine DNA methyltransferase (MGMT) is a
DNA repair protein over expressed in majority of
cancers including melanoma. The purpose of this study
is to show that MGMT inhibition not only decreases drug
mediated resistance, but also inhibits the primary and
metastatic melanoma growth.

METHODS
In this study, we used BRAF-mutated(V600E) primary
and metastatic melanoma cells to investigate the
combination therapeutic effect (Dabrafenib, Trametinib,
Disulfiram/Cu, and Temozolomide) using cell viability
assay. We also investigated the effects of these drug
combinations on effector molecules of the BRAF/MAPK

signaling pathway associated with melanoma by
western blot analysis and furthermore, MGMT
interacting partners that promotes melanoma growth
was detected by protein-protein interaction.
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RESULTS
The combination therapy significantly inhibited the
growth of primary as well as metastatic melanoma
growth compared to single agents, or combination of
BRAF/MEK inhibitors.
The combination therapy
significantly inhibited MAPK signaling pathway to inhibit
the melanoma growth. We show that triple lock –
upstream and downstream, along the MAPK pathway effectively restores durable BRAF and MEK inhibitor
activity and significantly sensitizes melanoma cells to
Temozolomide. The advantage of a multiple lock
approach on the MAPK pathway is substantiated by the
lack of signaling cross talk. MGMT is interacting with
oncogene (cMYC) to promote the melanoma growth.
Figure. 1

CONCLUSIONS
 In this study, we showed that combination of BRAF,
MEK and MGMT inhibitors significantly inhibited
primary as well as metastatic melanoma tumor
growth.
Figure3
 Combination therapy significantly inhibited MGMT,
BRAF - MEK Pathway and induced PARP cleavage
to inhibit melanoma growth.
 MGMT is interacting
melanoma growth
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